Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeRecommendationRSV RiskRSV RiskOverviewDisparitiesAbout ABRYSVOAbout ABRYSVOMaternal Immunization with ABRYSVOStudy Design & Efficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOCoverageResourcesResourcesMaterialsVideosRequest A RepMaternal RSV Vaccine Planner
Prescribing InformationIndications AdultPatient Site
Help address disparities that leave some babies at increased risk for RSV1-3 Maternal vaccination rates are consistently lower for Medicaid patients compared to those on commercial insurance3

Maternal Vaccination Rates for 2025-2026 season (up to January 2026)*

 Based on insurance coverage. Vaccination rates for pregnant patients were calculated using IQVIA LAAD database (medical and pharmacy adjudicated claims). Eligible cohorts of pregnant patients were tracked from July 2024 through June 2025 for flu/Tdap vaccination and from September 2025 through January 2026 for RSV maternal vaccination. Vaccination rates reflect estimates of real-world activity. All rights reserved.3Your recommendation is the #1 driver of vaccination4Explore resources to support your confident ABRYSVO recommendation.Get AccessLoading For eligible pregnant individuals younger than 19 years of age, ABRYSVO® is available through the Vaccines for Children (VFC) program.5 VFC is a federally funded program that provides vaccines at no cost to eligible individuals younger than 19 years of age.6†Despite the risk of hospitalization due to RSV, 44% of infants did not receive any form of RSV protection last season5*
Transmitted from person to person via respiratory droplets2

RSV can infect the airways of an individual2


Prevention is important. Treatment options are limited to supportive care2
ReferencesChildren qualify for the VFC program if they are younger than 19 years of age, and either uninsured, underinsured, Medicaid eligible, or American Indian or Alaska Native.7LAAD=Longitudinal Access and Adjudication Data; RSV=respiratory syncytial virus; Tdap=tetanus, diphtheria, and pertussis.RSV RiskInsurance coverageLearn more about coverage for ABRYSVO for eligible pregnant patients.Explore NowLoading
Order your ABRYSVO supply Order Now Loading Receive Updates About ABRYSVO Register Now Loading Request a Pfizer Sales Representative Connect Now Loading Order your ABRYSVO supply Order Now Loading Receive Updates About ABRYSVO Register Now Loading Request a Pfizer Sales Representative Connect Now Loading

References:

Suh M, Movva N, Jiang X, et al. Healthcare utilization among infants covered by Medicaid and newly diagnosed with respiratory syncytial virus. Open Forum Infect Dis. 2024;11(4):ofae174.Centers for Disease Control and Prevention. Provisional Natality on CDC WONDER online database. Accessed July 16, 2026. http://wonder.cdc.gov/natality-expanded-provisional.htmlData on file. Pfizer Inc.Centers for Disease Control and Prevention. Adult immunization standards. Updated August 9, 2024. Accessed July 25, 2025. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.htmlCenters for Disease Control and Prevention. Pediatric/VFC vaccine price list. Updated June 18, 2026. Accessed July 17, 2026. https://www.cdc.gov/vaccines-for-children/media/pdfs/2026/06/Pediatric-VFC-Vaccine-Price-List-06-16-26.pdfCenters for Disease Control and Prevention. About the vaccines for children (VFC) program. Updated September 30, 2025. Accessed July 17, 2026. https://www.cdc.gov/vaccines-for-children/about/index.htmlCenters for Disease Control and Prevention. Vaccines for Children (VFC) program eligibility. Updated September 30, 2025. Accessed July 17, 2026. https://www.cdc.gov/vaccines-for-children/hcp/program-eligibility/index.html

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1G-USA-3188
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)  
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)  
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO. IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerProBy clicking Go to VaxAssist.com, you will be redirected to VaxAssist by Pfizer, where your patients can check eligibility and vaccine options. For additional information on ABRYSVO, please see Important Safety Information.